

Study of Fibrotest, NAFLD Fibrosis score, Fibrosis 4 score and Transient Elastography as non invasive tools of liver fibrosis in patients with Non alcoholic fatty liver disease

Thesis

*Submitted for Partial Fulfillment of MD Degree
in Internal Medicine*

By

Karim Samy Abd Allah Bahnasy

M.B.B.Ch. M.Sc,

Faculty of Medicine - Ain Shams University

Under Supervision of

Prof. Dr. Khaled Abd El Hameed Mohamed

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine- Ain Shams University*

Prof. Dr. Sherif Monier Mohamed

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Assist. Prof. Dr. Deena Samir Mohamed

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University*

Assist. Prof. Dr. Sherif Sadek Taha

*Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Dr. Hosam Samir El Baz

*Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine- Ain Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَّانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

No words can express my deepest appreciation and profound respect to **Prof. Dr. Khaled Abd El Hameed Mohamed**, Professor of Internal Medicine and Gastroenterology, Ain Shams University, for his continuous guidance and support. He has generously devoted much of his time and her effort for planning and supervision of this study.

Also, my profound gratitude to **Prof. Dr. Sherif Monier Mohamed**, Professor of Internal Medicine and Gastroenterology, Ain Shams University, for his kind supervision and support. It was great honor to work under his supervision.

I would like also to thank **Assist. Prof. Dr. Deena Samir Mohamed**, Assistant Professor of Internal Medicine and Gastroenterology, Ain Shams University, for her support, help and constructive criticism during this work.

I would like also to thank **Assist. Prof. Dr. Sherif Sadek Taha**, Assistant Professor of Internal Medicine and Gastroenterology, Ain Shams University, for his support and help during this work.

Also, my profound gratitude to **Dr. Hosam Samir El Baz**, Lecturer of Internal Medicine and Gastroenterology, Ain Shams University, for his great care and support.

Last but not least, I dedicate this work to **my family**, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.

Karim Samy



List of Contents

Subject	Page No.
List of Abbreviations	I
List of Tables	III
List of Figures.....	VII
Introduction.....	1
Aim of the Work.....	5
Review of Literature	
Chapter (1): Fatty Liver Disease.....	6
Chapter (2): Liver Fibrosis	42
Chapter (3): Noninvasive Assessment of Hepatic Fibrosis.....	60
Patients and Methods	70
Results	79
Discussion.....	121
Summary.....	130
Conclusion	134
Recommendations	135
References.....	136
Arabic Summary.....	—

List of Abbreviations

Abb.	Full term
A2M	Alpha-2 macroglobulin
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
APRI	Aspartate-to-platelet ratio index
AST	Aspartate aminotransferase
AUROC	Area under the ROC curve
BMI	Body mass index
CYP2E1	Cytochrome P450 2E1
DPP-4I	Dipeptidyl peptidase-4 inhibitors
FGF	Fibroblast growth factor
FIB-4	Fibrosis-4
FT	FibroTest
GGT	Gamma-glutamyltranspeptidase
GLP-1 RA	Glucagon-like peptide-1 receptor agonists
HAI	Histology activity index
HIV	Human immunodeficiency virus
IL-18	Interleukin-18
IL-1β	Interleukin-1beta
IL-6	Interleukin-6
INR	International normalized ratio
kPa	Kilopascals
LSM	Liver stiffness measurement
NAFLD	Non alcoholic fatty liver disease
NASH	Nonalcoholic steatohepatitis
NFS	NAFLD fibrosis score
PDGF	Platelet derived growth factor

Abb.	Full term
PPARα	Peroxisome proliferator activated receptor alpha
PPARγ	Peroxisome proliferator activated receptor gamma
PTT	Partial thromboplastin time
TE	Transient elastography
TGF-β	Transforming growth factor-beta
TIMP-1	Metalloproteinase-1
TNF-α	Tumor necrosis factor-alpha
TZDs	Thiazolidinediones

List of Tables

Table	Title	Page
1	Risk factors associated with NAFLD	12
2	Common causes of secondary hepatic steatosis	26
3	Histology activity index (HAI – Knodell Score)	57
4	Proportions of patients according to severity of liver fibrosis	80
5	Proportions of patients according to metavir staging	81
6	Sex distribution among studied patients	82
7	Age distribution among proportions of patients with either mild or moderate to severe fibrosis	83
8	Sex distribution among proportions of patients with either mild or moderate to severe fibrosis	84
9	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the presence of diabetes mellitus	85
10	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the body mass index	87
11	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards total cholesterol levels	88

Table	Title	Page
12	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum triglyceride levels	89
13	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards liver function tests	91
14	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards complete blood count	96
15	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards kidney function tests	98
16	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum a2 macroglobulin level	100
17	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum haptoglobin level	101
18	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum apolipoprotein A1 level	102

Table	Title	Page
19	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards AST to platelet ratio index	104
20	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the FIB_4 score	105
21	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the FIB_4 score	106
22	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the NAFLD fibrosis score	108
23	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the NAFLD fibrosis score	110
24	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the fibroscan	111
25	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the fibro scan	113

Table	Title	Page
26	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the fibrotes	114
27	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the fibrotest	116
28	Accuracy of fibrotest in the detection of fibrosis metavir stage F2 and higher	117
29	Accuracy of fibroscan in the detection of fibrosis	118
30	Accuracy of NAFLD fibrosis score in the detection of fibrosis	119
31	Accuracy of FIB_4 score in the detection of fibrosis	120

List of Figures

Figure	Title	Page
1	Fat induced inflammation and fibrosis in NAFLD	16
2	Extracellular matrix accumulation in subendothelial space activates quiescent hepatic stellate cells leading to the loss of hepatocyte microvilli and disappearance of endothelial fenestrations	46
3	Hepatic stellate cells are a heterogenous population of fibrogenic cells	47
4	Proportions of patients according to liver fibrosis severity	80
5	Proportions of patients according to metavir staging	81
6	Sex distribution among studied patients	82
7	Age distribution among proportions of patients with either mild or moderate to severe fibrosis	83
8	Sex distribution among proportions of patients with either mild or moderate to severe fibrosis	84
9	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the presence of diabetes mellitus	86

Figure	Title	Page
10	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the body mass index	87
11	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards total cholesterol levels	88
12	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum triglyceride levels	89
13	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards ALT levels (U/L)	92
14	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards AST levels (U/L)	92
15	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards alkaline phosphatase levels (U/L)	93
16	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards GGT levels (U/L)	93

Figure	Title	Page
17	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards total bilirubin levels (Umol/l)	94
18	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards INR values	94
19	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards white blood cell count (mm ³)	96
20	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards hemoglobin level (g/dl)	97
21	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards platelet count (mm ³)	97
22	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards kidney function test (mg/dl)	99

Figure	Title	Page
23	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum α_2 macroglobulin level (g/l)	100
24	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum haptoglobin level (g/l)	101
25	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards serum apolipoprotein A1 level (g/l)	103
26	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the AST to platelet ratio index	104
27	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the FIB_4 score	105
28	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the FIB_4 score	107

Figure	Title	Page
29	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the NAFLD fibrosis score	108
30	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the NAFLD fibrosis score	110
31	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the fibroscan (kPa)	111
32	Comparison between the proportions of patients according to the 5 stages of the metavir staging system of liver fibrosis as regards the fibro scan (kPa)	113
33	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the fibrotest	114
34	Comparison between the proportions of patients with either mild or moderate to severe fibrosis as regards the fibrotest	116
35	Accuracy of fibrotest in the detection of fibrosis	117